New Investigational Drug for CF Patients with NTM Infection

Trial Objective

New Investigational Drug for CF Patients with NTM InfectionThis study will determine if a new investigational drug helps treat ongoing nontuberculous mycobacterial (NTM) infection in adults with cystic fibrosis. The medication, Molgramostim Nebulized Solution, is not an antibiotic, but is designed to stimulate an immune response to better fight infection. Participants will nebulize the drug once a day after their full morning routine. Everyone in the trial will get the active drug.

Enrollment

This trial is active and currently recruiting.

Who Can Participate

Adults who are diagnosed with cystic fibrosis and have ongoing mycobacterial infection.

Age: 18+    Gender: Any Gender


Estimated Time Commitment

Study involvement will last for about 18 months.

Participants will nebulize the drug for 48 weeks. There are 19 visits that take 3-4 hours each.



Compensation

Provided

Trial Contact

For more information, contact:

Alexandria Leonhardt

Alexandria Leonhardt
303.398.1453

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

SAVARA

Principal Investigators


Request More Information

*
*
*
*